The path forward for T cell engagers in patients with prostate cancer - PubMed
3 hours ago
- #immunotherapy
- #T cell engagers
- #prostate cancer
- T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses.
- TCEs have shown promising clinical responses in metastatic castration-resistant prostate cancer and are in phase 3 trials.
- The article reviews mechanisms of action for CD3-targeted and CD28-targeted TCEs and their clinical development in prostate cancer.
- Proposes innovative clinical trials to understand efficacy, toxicity, and develop predictive biomarkers, combination strategies, and toxicity management.
- Aims to deliver broad clinical benefits for patients with lethal prostate cancer.